Cyber Swan Sale

50% Off Elite

Days

Hours

Mins

Sec

Get our most powerful screeners, new charting tools, and the fastest ad-free experience at our best price ever. One last chance.

MNOV

Medicinova Inc

Dec 05 • 04:00PM ET

1.56

+0.01 0.65 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX MRK GILD AMGN BIIB REGN BMY INCY ACAD NBIX

| Held by: VXF IWC DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.24	Insider Own	5.24%	Shs Outstand	49.05M	Perf Week	7.59%
Market Cap	76.51M	Forward P/E	-	EPS next Y	-0.38	Insider Trans	0.00%	Shs Float	46.48M	Perf Month	3.31%
Enterprise Value	44.21M	PEG	-	EPS next Q	-0.12	Inst Own	19.42%	Short Float	1.22%	Perf Quarter	23.81%
Income	-12.01M	P/S	294.27	EPS this Y	-117.39%	Inst Trans	-0.06%	Short Ratio	0.59	Perf Half Y	10.64%
Sales	0.26M	P/B	1.74	EPS next Y	24.00%	ROA	-22.73%	Short Interest	0.57M	Perf YTD	-25.71%
Book/sh	0.90	P/C	2.35	EPS next 5Y	-20.26%	ROE	-24.26%	52W High	2.37 -34.18%	Perf Year	-32.17%
Cash/sh	0.66	P/FCF	-	EPS past 3/5Y	-2.62% 5.56%	ROIC	-27.27%	52W Low	1.13 38.05%	Perf 3Y	-40.91%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-14.01%	Volatility	3.50% 5.52%	Perf 5Y	-73.74%
Dividend TTM	-	EV/Sales	170.04	EPS Y/Y TTM	-16.67%	Oper. Margin	-5185.49%	ATR (14)	0.08	Perf 10Y	-55.17%
Dividend Ex-Date	-	Quick Ratio	9.86	Sales Y/Y TTM	-86.54%	Profit Margin	-4656.65%	RSI (14)	59.79	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.86	EPS Q/Q	-6.87%	SMA20	5.51%	Beta	0.50	Target Price	9.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	14.77%	Rel Volume	0.10	Prev Close	1.55
Employees	13	LT Debt/Eq	0.00	Earnings	Nov 13 BMO	SMA200	13.10%	Avg Volume	954.22K	Price	1.56
IPO	Dec 07, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	98,817	Change	0.65%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-10-21	Initiated	Maxim Group	Buy	$15
Mar-25-19	Resumed	B. Riley FBR	Buy	$22
Mar-28-18	Initiated	B. Riley FBR, Inc.	Buy	$22
Apr-18-17	Initiated	Credit Suisse	Outperform
Jan-04-13	Reiterated	Ladenburg Thalmann	Buy	$10.50 → $6
May-24-12	Downgrade	MLV & Co	Buy → Hold
Oct-18-11	Reiterated	MLV Capital	Buy	$13 → $6
Jun-22-11	Initiated	Global Hunter Securities	Buy	$4
May-12-10	Initiated	Wedbush	Outperform	$13
Nov-12-08	Reiterated	Ladenburg Thalmann	Buy	$22 → $6
May-15-08	Initiated	Rodman & Renshaw	Mkt Outperform	$9
Jul-09-07	Initiated	Punk, Ziegel & Co	Buy	$22

Show Previous Ratings

Dec-01-25 06:00PM	Message from the CEO to MediciNova Shareholders (GlobeNewswire)
Nov-18-25 06:00AM	MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor (GlobeNewswire)
Nov-12-25 05:22PM	MediciNova: Q3 Earnings Snapshot (Associated Press Finance)
Nov-06-25 06:00PM	MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards (GlobeNewswire) -7.28%
Nov-04-25 07:00AM	MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) (GlobeNewswire) -5.33%
08:55PM	Loading…
Oct-31-25 08:55PM	MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis (TipRanks) +39.50% -9.64%
Oct-30-25 07:00PM	MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication (GlobeNewswire)
Oct-06-25 08:00AM	MediciNova to Present at the LD Micro Main Event XIX Investor Conference (GlobeNewswire)
Sep-23-25 07:13AM	MediciNova concludes subject enrolment in trial of MN-166 (Clinical Trials Arena)
Sep-22-25 08:00AM	MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast) (GlobeNewswire)
Sep-16-25 08:00AM	MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND (GlobeNewswire)
Sep-08-25 09:00AM	MediciNova Provides Shareholder Update on Key Developments (GlobeNewswire)
Sep-03-25 07:00AM	MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-26-25 07:00PM	MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial (GlobeNewswire)
Aug-14-25 05:30PM	MediciNova: Q2 Earnings Snapshot (Associated Press Finance)
07:30PM	Loading…
Jul-31-25 07:30PM	MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million (GlobeNewswire) +7.92%
Jul-24-25 06:00AM	MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials (GlobeNewswire)
Jun-17-25 09:20AM	MediciNova price target lowered to $5 from $6 at B. Riley (TipRanks) -5.26%
May-13-25 04:56PM	MediciNova: Q1 Earnings Snapshot (Associated Press Finance) -6.16%
Apr-14-25 07:00PM	MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025 (GlobeNewswire)
Apr-08-25 07:00PM	First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients (GlobeNewswire) +6.01%
Dec-05-24 06:00PM	MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND (GlobeNewswire)
Nov-19-24 09:00AM	MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders (GlobeNewswire) +5.56%
Nov-14-24 06:00PM	MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver (GlobeNewswire) -8.75%
Nov-13-24 05:08PM	MediciNova: Q3 Earnings Snapshot (Associated Press Finance) -12.28%
Nov-11-24 06:00PM	MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis (GlobeNewswire) +49.02%
Oct-23-24 07:00PM	MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) (GlobeNewswire)
Sep-30-24 09:00AM	MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire) +9.95%
Sep-09-24 07:00PM	MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND (GlobeNewswire) -9.05%
Sep-03-24 07:00PM	MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting (GlobeNewswire) +10.00% +7.27%
07:00PM	Loading…
Aug-29-24 07:00PM	MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition (GlobeNewswire) +14.50%
Jun-20-24 06:00AM	MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations (GlobeNewswire)
Jun-05-24 06:00AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer (GlobeNewswire)
Jun-03-24 06:00AM	MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 (GlobeNewswire) +8.09%
May-28-24 06:00AM	MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions (GlobeNewswire)
May-20-24 06:00AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer (GlobeNewswire)
May-14-24 06:00AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome (GlobeNewswire)
May-10-24 08:52AM	MNOV Stock Earnings: MediciNova Misses EPS for Q1 2024 (InvestorPlace)
May-09-24 07:45PM	MediciNova: Q1 Earnings Snapshot (Associated Press Finance) +8.15%
May-07-24 06:00AM	MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) (GlobeNewswire)
Apr-02-24 07:00PM	MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) (GlobeNewswire)
Mar-26-24 07:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan (GlobeNewswire) +8.09%
Mar-20-24 07:00PM	MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society (GlobeNewswire)
Mar-12-24 06:30AM	MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology (GlobeNewswire)
Jan-17-24 06:00AM	MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China (GlobeNewswire)
Dec-21-23 06:00PM	MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology (GlobeNewswire)
Dec-06-23 06:00PM	MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe (GlobeNewswire)
Nov-19-23 06:00PM	MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology (GlobeNewswire)
Nov-10-23 09:57AM	MediciNova: Q3 Earnings Snapshot (Associated Press Finance)
Oct-27-23 01:00AM	MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria (GlobeNewswire)
Oct-10-23 07:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada (GlobeNewswire)
Oct-04-23 07:00PM	MediciNova Receives Gene Therapy Milestone Payment (GlobeNewswire)
Sep-29-23 09:11AM	MNOV: Positive Results for MN-166 in Chlorine Gas-Induced Acute Lung Injury Model (Zacks)
Sep-27-23 07:00PM	MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury (GlobeNewswire)
Aug-21-23 08:00AM	MNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury (Zacks)
Aug-17-23 07:00PM	MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology (GlobeNewswire) -6.63%
Aug-16-23 07:00PM	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe (GlobeNewswire) +6.93%
Aug-15-23 07:00PM	MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe (GlobeNewswire)
Aug-14-23 07:00PM	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe (GlobeNewswire)
Aug-10-23 02:12PM	MediciNova: Q2 Earnings Snapshot (AP Finance)
Jul-23-23 09:56AM	With 49% ownership, MediciNova, Inc. (NASDAQ:MNOV) has piqued the interest of institutional investors (Simply Wall St.)
Jun-29-23 06:00AM	MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting (GlobeNewswire)
May-30-23 05:00AM	MNOV: Compelling Buying Opportunity in Differentiated Small-Cap Biotech (Zacks Small Cap Research)
May-14-23 07:00PM	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe (GlobeNewswire)
May-12-23 07:47PM	MediciNova: Q1 Earnings Snapshot (AP Finance)
Apr-30-23 07:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada (GlobeNewswire)
Mar-22-23 11:19AM	We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth (Simply Wall St.)
Mar-09-23 06:00PM	MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury (GlobeNewswire)
Feb-27-23 04:57AM	MNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled (Zacks Small Cap Research)
Feb-20-23 06:00PM	MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics (GlobeNewswire)
Feb-08-23 06:00PM	MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID (GlobeNewswire)
Jan-30-23 06:00PM	MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder (GlobeNewswire)
Jan-12-23 06:00PM	MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma (GlobeNewswire)
Jan-10-23 10:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada (GlobeNewswire)
Jan-09-23 10:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil (GlobeNewswire)
Jan-05-23 06:00PM	MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast) (GlobeNewswire) +6.22%
Dec-06-22 06:00PM	MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation (GlobeNewswire)
Dec-05-22 06:00PM	MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse (GlobeNewswire)
Nov-29-22 05:43PM	13 Best Biotech Penny Stocks To Buy Now (Insider Monkey) -5.26%
Nov-18-22 05:40AM	MNOV: Well Financed to Get Through Tough Market Conditions (Zacks Small Cap Research)
Oct-13-22 10:50AM	We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth (Simply Wall St.)
Sep-15-22 07:00PM	MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference (GlobeNewswire)
Sep-14-22 07:00PM	MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma (GlobeNewswire)
09:03AM	MediciNova Poised To Receive Canadian Patents For Cholesterol Candidates (Benzinga)
Sep-13-22 07:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada (GlobeNewswire)
Aug-19-22 06:23AM	MNOV: Phase 2 Trial of MN-001 in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia Underway (Zacks Small Cap Research) -5.00%
Aug-16-22 06:30AM	MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID (GlobeNewswire)
Aug-09-22 07:00PM	MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation (GlobeNewswire)
Jul-27-22 06:30AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea (GlobeNewswire)
Jul-26-22 06:30AM	MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia (GlobeNewswire)
Jul-21-22 07:00PM	MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast) (GlobeNewswire)
Jun-29-22 07:00PM	MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury (GlobeNewswire)
Jun-22-22 07:00PM	MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan (GlobeNewswire)
Jun-13-22 06:35AM	MNOV: Positive Results for MN-166 (Ibudilast) in Patients at Risk of Acute Respiratory Distress Syndrome (Zacks Small Cap Research)
Jun-08-22 09:05AM	MediciNova Posts Promising Data From COVID-19 Treatment Candidate (Benzinga) +8.94%
06:30AM	MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome (GlobeNewswire)
May-25-22 06:10AM	MNOV: Plans for Phase 2 Study of MN-001 (tipelukast) in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia (Zacks Small Cap Research)
May-06-22 09:48AM	We're Not Very Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Rate (Simply Wall St.)
Apr-21-22 07:00PM	MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference (GlobeNewswire)
Apr-20-22 07:00PM	MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research (GlobeNewswire)

MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Cyber Swan Sale

50% Off Elite

MNOV

Medicinova Inc

Upgrade your FINVIZ experience